Trilogy Capital’s Microbot Medical MBOT Stock Holding History

Trilogy Capital’s Portfolio MBOT Stock Details MBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	–	–	393
2018 Q3	$0	Buy	+1	New	+$9	﹤0.01%	640
2018 Q2	–	Hold	0	–	–	–	606
2018 Q1	–	Hold	0	–	–	–	501

Other funds holding MBOT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Trilogy Capital's MBOT Position: Q4 2018 in Review

Trilogy Capital sold out of Microbot Medical (MBOT) in Q4 2018, closing a stake of 1 share.

Trilogy Capital first reported a position in MBOT in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 29 funds tracked by Wall St. Rank hold MBOT as of Q4 2018.

Trilogy Capital reported no remaining Microbot Medical position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 1 Microbot Medical share in Q4 2018.
Trilogy Capital first reported a position in Microbot Medical in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Microbot Medical position peaked at $0 in Q3 2018.
29 funds tracked by Wall St. Rank held Microbot Medical as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.